U.S. Banks Stock News

NYSE:MANE
NYSE:MANEPharmaceuticals

Assessing Veradermics (MANE) Valuation After Recent 3.6% Share Price Move

Veradermics stock in focus after recent price move Veradermics (MANE) drew fresh attention after a single day gain of about 3.6%, putting the US$38.48 share price and the company’s dermatology focused pipeline on more investors’ radar. See our latest analysis for Veradermics. The 3.6% one day share price return comes after a relatively muted 1.9% year to date share price return, suggesting interest around Veradermics is picking up only gradually rather than in a sharp momentum shift. If this...
NYSE:ETN
NYSE:ETNElectrical

Assessing Eaton (ETN) Valuation After Strong Earnings And Positive 2026 Guidance

Eaton (ETN) is back in focus after reporting its fourth quarter and full year 2025 results along with fresh 2026 guidance, giving investors new data on sales, earnings and expected organic growth. See our latest analysis for Eaton. Eaton shares have been on a strong run, with the latest share price at $373.82 and a 1 month share price return of 15.2%, alongside a 1 year total shareholder return of 18.36%. The 5 year total shareholder return of 228.09% points to sustained momentum as investors...
NasdaqGS:DKNG
NasdaqGS:DKNGHospitality

How DraftKings’ New Crypto.com Event Contracts Will Impact DraftKings (DKNG) Investors

In early February 2026, DraftKings Inc. announced an agreement with Crypto.com | Derivatives North America to broaden DraftKings Predictions, introducing the first player-specific sports event contracts for the NFL and NBA and expanding into additional sports under CFTC oversight. The collaboration also lays groundwork for future event contracts in politics, culture, and entertainment, positioning DraftKings Predictions as a broader federally regulated prediction platform beyond traditional...
NasdaqCM:BLTE
NasdaqCM:BLTEPharmaceuticals

Belite Bio (BLTE) Valuation Check After Completing Enrollment In Pivotal DRAGON II Trial

Belite Bio (BLTE) completed enrollment of 60 adolescents in its global Phase 2/3 DRAGON II trial for tinlarebant in Stargardt disease type 1, marking a key clinical milestone that investors often watch closely. See our latest analysis for Belite Bio. The latest clinical milestone comes on top of a strong run in the shares, with Belite Bio’s 30 day share price return of 18.63% and 90 day share price return of 77.63%. Its 1 year total shareholder return of 249.18% and 3 year total shareholder...
NYSE:PEG
NYSE:PEGIntegrated Utilities

Long Island Contract Extension and Bank Upgrades Could Be A Game Changer For Public Service Enterprise Group (PEG)

In late 2025 and January 2026, Public Service Enterprise Group gained attention as major banks upgraded their views and New York State approved the extension of its operations services agreement with the Long Island Power Authority through December 31, 2030. Together with comments about potential regulated generation opportunities in New Jersey, these developments highlighted how PSEG’s regulated and contracted businesses may shape its longer-term profile. We’ll now examine how the Long...
NasdaqGS:ZS
NasdaqGS:ZSSoftware

Is It Time To Reassess Zscaler (ZS) After The Recent Share Price Slump

If you are wondering whether Zscaler is starting to look attractively priced or still expensive, this article will walk through what the current share price might be implying about its value. The stock last closed at US$167.33, with returns of 16.3% decline over 7 days, 22.8% decline over 30 days, 24.1% decline year to date and 18.6% decline over 1 year, set against a 25.0% gain over 3 years and 26.1% decline over 5 years. Recent news coverage has focused on Zscaler as a key name in cloud...
NasdaqGS:WSBC
NasdaqGS:WSBCBanks

WesBanco (WSBC) Is Up 5.2% After Strong Q4 EPS And New Preferred Dividend Plan – What's Changed

WesBanco, Inc. recently reported its fourth-quarter and full-year 2025 results, with quarterly net interest income rising to US$222.3 million and net income to US$91.11 million, and also announced that beginning in the first quarter of 2026, dividends on its Series B preferred stock will be US$4.24 million per quarter. An interesting angle for investors is that quarterly earnings per share improved year on year even as full-year earnings per share from continuing operations remained broadly...
NasdaqGS:VEON
NasdaqGS:VEONWireless Telecom

Assessing VEON (NasdaqGS:VEON) Valuation As 2025 Guidance Rises And Uzbekistan Tech Initiatives Advance

Guidance upgrade and Uzbekistan tech push put VEON (NasdaqGS:VEON) in focus VEON (NasdaqGS:VEON) has raised its preliminary 2025 revenue guidance to a projected 24% to 26% year on year range, while also opening a new network operations center and launching AI-focused BuildX in Uzbekistan. See our latest analysis for VEON. VEON’s recent guidance upgrade and Uzbekistan tech initiatives come after a period where short term share price returns have been mixed, with a 7 day share price return of a...
NasdaqGS:ITRI
NasdaqGS:ITRIElectronic

How Itron’s New AI Grid Edge Alliances Could Reshape Risk Management for Itron (ITRI) Investors

Itron, Inc. and key partners, including Pacific Gas and Electric Company, San Diego Gas & Electric, Microsoft and Snowflake, recently expanded collaborations and unveiled new AI-enabled Grid Edge Intelligence and Resiliency Solutions aimed at wildfire mitigation, outage reduction and more flexible home and grid electrification. Together, these alliances and product advances highlight Itron’s role in unifying real-time grid data, AI and distributed intelligence to help utilities manage rising...
NYSE:PBH
NYSE:PBHPharmaceuticals

How Mixed Q3 Results, Buybacks and Pillar5 Deal At Prestige (PBH) Have Changed Its Investment Story

In early February 2026, Prestige Consumer Healthcare reported third-quarter fiscal 2026 results showing lower sales and earnings, narrowed full-year revenue guidance to about US$1.10 billion, and detailed continued share repurchases and the recent Pillar5 acquisition amid supply constraints in its Clear Eyes brand. The company highlighted strong free cash flow, reduced leverage, and the flexibility to fund brand investment, selective M&A, and sizeable buybacks at the same time. With recent...
NasdaqCM:DNTH
NasdaqCM:DNTHBiotechs

How Investors Are Reacting To Dianthus Therapeutics (DNTH) US$600 Million Universal Shelf Registration

Dianthus Therapeutics, Inc. recently filed a universal shelf registration of up to US$600 million, covering common and preferred stock, debt securities, warrants and units, while also participating in the Guggenheim Emerging Outlook: Biotech Summit 2026 through a CEO fireside chat and investor meetings. This broad financing framework gives the clinical-stage biotech considerable flexibility in how and when it may access capital across different security types. Next, we will examine how the...
NYSE:ZTO
NYSE:ZTOLogistics

ZTO Express (ZTO) Is Up 8.9% After Funding Buybacks With Low-Coupon Convertibles - Has The Bull Case Changed?

In early February 2026, ZTO Express (Cayman) Inc. issued 2025 guidance calling for higher revenues but lower gross profit versus 2024, and completed a US$1.50 billion callable, convertible senior unsecured bond offering due 2031 priced at par with a 0.925% fixed coupon. The combination of rising parcel volumes, thinner margins, and using low-coupon convertible debt to fund refinancing, capped calls, and share repurchases adds a complex layer to how investors may assess ZTO’s capital...
NasdaqGS:GNTX
NasdaqGS:GNTXAuto Components

What Gentex (GNTX)'s Strong Q4 Results, Guidance and Buybacks Mean For Shareholders

Gentex Corporation recently reported fourth-quarter 2025 results, with sales rising to US$644.4 million and net income increasing to US$92.96 million, alongside higher earnings per share than a year earlier. The company also issued multi-year revenue guidance through 2027 and completed a US$99.08 million share repurchase, underscoring management’s confidence in its operating outlook and capital allocation approach. We’ll now examine how Gentex’s upbeat multi-year revenue guidance shapes its...
NYSE:YUMC
NYSE:YUMCHospitality

Yum China Holdings (YUMC) Is Up 14.6% After Strong Q4 Results And Faster Store Expansion - Has The Bull Case Changed?

Yum China Holdings reported past fourth-quarter 2025 results showing higher sales of US$2,627 million and revenue of US$2,823 million, with net income rising to US$140 million, alongside a 21% dividend increase and continued share repurchases. The company also added 1,706 net new stores in 2025, bringing its network to 18,101 locations and highlighting rapid nationwide scale-up in China’s restaurant market. Against this backdrop, we’ll explore how Yum China’s accelerated store expansion...